Trial Profile
Effect of ezetimibe on PCSK9 concentrations in patients with type 2 diabetes and dyslipidemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2016
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; HMG-CoA reductase inhibitors
- Indications Hypercholesterolaemia; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 12 Aug 2015 New trial record